poisar

Stocks · News reference

UBS Maintains Buy on McKesson, Raises Price Target to $1200

Benzinga Newsdesk

UBS analyst Kevin Caliendo maintains McKesson (NYSE:MCK) with a Buy and raises the price target from $1080 to $1200.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

MCK
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Sara Appino

    AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

    AbbVie and Pfizer are compared as healthcare investment options in 2026. AbbVie has successfully navigated patent cliff challenges with strong growth from Skyrizi and Rinvoq offsetting Humira losses, while Pfizer is rebuilding its pipeline around obesity drugs and awaiting key pipeline readouts. The article recommends AbbVie as the clearer choice for investors seeking current pharmaceutical exposure, though both companies face biosimilar competition and regulatory pressures.

    ABBVPFEMCKCAHCOR